Halozyme Therapeutics Balance Sheet Health
Financial Health criteria checks 3/6
Halozyme Therapeutics has a total shareholder equity of $249.2M and total debt of $1.5B, which brings its debt-to-equity ratio to 601%. Its total assets and total liabilities are $1.9B and $1.6B respectively. Halozyme Therapeutics's EBIT is $332.9M making its interest coverage ratio 25.9. It has cash and short-term investments of $483.3M.
Key information
601.0%
Debt to equity ratio
US$1.50b
Debt
Interest coverage ratio | 25.9x |
Cash | US$483.28m |
Equity | US$249.18m |
Total liabilities | US$1.64b |
Total assets | US$1.89b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: HALO *'s short term assets ($879.0M) exceed its short term liabilities ($115.2M).
Long Term Liabilities: HALO *'s short term assets ($879.0M) do not cover its long term liabilities ($1.5B).
Debt to Equity History and Analysis
Debt Level: HALO *'s net debt to equity ratio (407.1%) is considered high.
Reducing Debt: HALO *'s debt to equity ratio has increased from 61.1% to 601% over the past 5 years.
Debt Coverage: HALO *'s debt is well covered by operating cash flow (24.6%).
Interest Coverage: HALO *'s interest payments on its debt are well covered by EBIT (25.9x coverage).